Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.

Publikation

Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.

Wissenschaftlicher Artikel/Review - 26.09.2022

De Marchis Gian Marco, Dittrich Tolga, Malik Rainer, Zietz Annaelle, Kriemler Lilian, Ference Brian A, Dichgans Martin, Georgakis Marios K

Zitation

De Marchis G, Dittrich T, Malik R, Zietz A, Kriemler L, Ference B, Dichgans M, Georgakis M. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. Atherosclerosis 2022; 361:41-46.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Atherosclerosis 2022; 361

Veröffentlichungsdatum

26.09.2022

eISSN (Online)

1879-1484

Seiten

41-46

Kurzbeschreibung/Zielsetzung

Post hoc analyses of clinical trials show that PCSK9 inhibitors might lower lipoprotein(a), but whether this effect contributes to reductions in cardiovascular risk remains unknown. We aimed to assess whether genetically proxied PCSK9 inhibition influences lipoprotein(a) (Lp(a)), and whether any such effect could mediate its effects on coronary artery disease (CAD) and ischemic stroke (IS).